Amgen Inc. (AMGN) FY2025 Q3 P&L / Income Statement

Amgen Inc. (AMGN) FY2025 Q3 P&L / Income Statement

Income statement for 2025-07-01 through 2025-09-30. View: Product and service (16 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

9,557,000,000 US dollars

Cost of sales

3,082,000,000 US dollars

Gross profit (calculated)

6,475,000,000 US dollars

Operating expenses (calculated)

3,949,000,000 US dollars

Operating income

2,526,000,000 US dollars

Other income (expense), net (calculated)

1,395,000,000 US dollars

Income before income taxes

3,921,000,000 US dollars

Provision for income taxes

705,000,000 US dollars

Net income

3,216,000,000 US dollars

Prolia

1,139,000,000 US dollars

Repatha

794,000,000 US dollars

ENBREL

580,000,000 US dollars

Otezla

585,000,000 US dollars

XGEVA

539,000,000 US dollars

EVENITY

541,000,000 US dollars

TEPEZZA

560,000,000 US dollars

BLINCYTO

392,000,000 US dollars

Nplate

457,000,000 US dollars

Kyprolis

359,000,000 US dollars

Aranesp

357,000,000 US dollars

TEZSPIRE

377,000,000 US dollars

KRYSTEXXA

320,000,000 US dollars

Vectibix

284,000,000 US dollars

Other products

1,853,000,000 US dollars

Other revenues

420,000,000 US dollars

Selling, general and administrative

1,720,000,000 US dollars

Research and development

1,900,000,000 US dollars

Other

329,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.